



Financial Results (Consolidated) for the Fiscal Year Ended March 31, 2026

FUJIFILM Holdings Corporation

Teiichi Goto

President and Chief Executive Officer

Date of annual shareholders' meeting: June 26, 2026

Projected date of the beginning of cash dividends: June 29, 2026

Projected date of annual securities report: June 24, 2026

Reference materials regarding operating results of the current fiscal year to be prepared: Yes

Meeting to explain operating results of the current fiscal year to be held: Yes

(Consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.)

May 12, 2026

URL: <https://holdings.fujifilm.com/en>

1. Results of the Fiscal Year Ended March 31, 2026 (From April 1, 2025 to March 31, 2026)

(1) OPERATING RESULTS

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen
%: Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Income before income taxes		Net income attributable to FUJIFILM Holdings	
	Yen	%	Yen	%	Yen	%	Yen	%
Year ended March 31, 2026	3,356,969	5.0	350,210	6.1	366,629	7.6	276,735	6.0
Year ended March 31, 2025	3,195,828	7.9	330,155	19.3	340,594	7.3	260,951	7.2

Note: Comprehensive income

Year ended March 31, 2026 ¥580,678 million (+131.4 %) Year ended March 31, 2025 ¥250,924 million (-51.7%)

	Net income attributable to FUJIFILM Holdings per share	Net income attributable to FUJIFILM Holdings per share (Assuming full dilution)	Return on FUJIFILM Holdings shareholders' equity	Ratio of income before income taxes to total assets	Ratio of operating income to revenue
	Yen	Yen	%	%	%
Year ended March 31, 2026	229.65	229.45	7.7	6.5	10.4
Year ended March 31, 2025	216.67	216.46	8.0	6.8	10.3

(Ref) Equity in net earnings of affiliated companies

Year ended March 31, 2026 ¥1,929 million Year ended March 31, 2025 ¥(1,320) million

(2) FINANCIAL POSITION

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

	Total assets	Total equity (Net asset)	FUJIFILM Holdings shareholders' equity	FUJIFILM Holdings shareholders' equity ratio to total assets	FUJIFILM Holdings shareholders' equity per share
	Yen	Yen	Yen	%	Yen
Year ended March 31, 2026	6,053,776	3,844,385	3,839,550	63.4	3,185.79
Year ended March 31, 2025	5,249,908	3,352,682	3,348,480	63.8	2,779.50

(3) CASH FLOWS

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

	Net cash provided by operating activities	Net cash used in investing activities	Net cash used in financing activities	Cash and cash equivalents at the end of year
Year ended March 31, 2026	410,555	(554,604)	120,249	170,553
Year ended March 31, 2025	428,162	(541,953)	108,883	172,111

2. Cash Dividends

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

	Cash dividends per share					Total cash dividends	Consolidated pay out ratio	Ratio of cash dividends to shareholders' equity
	1st Quarter	2nd Quarter	3rd Quarter	Year End	Year Total			
	Yen	Yen	Yen	Yen	Yen		%	%
Year ended March 31, 2025	-	30.00	-	35.00	65.00	78,358	30.0	2.4
Year ended March 31, 2026	-	35.00	-	35.00	70.00	84,419	30.5	2.3
Year ending March 31, 2027 (Forecast)	-	37.50	-	37.50	75.00		32.0	

3. Forecast for the Fiscal Year Ending March 31, 2027 (From April 1, 2026 to March 31, 2027)

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen
 %: Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Income before income taxes		Net income attributable to FUJIFILM Holdings		Net income attributable to FUJIFILM Holdings per share
		%		%		%		%	Yen
For the Year ending March 31, 2027	3,470,000	3.4	365,000	4.2	375,000	2.3	280,000	1.2	234.19

Note: The Company resolved at the meeting of the Board of Directors held on March 30, 2026 to carry out a share repurchase, and the share repurchase pursuant to this resolution was completed on April 30, 2026. (For details, please refer to the notice dated May 7, 2026, titled "Notice Regarding Completion of Share Repurchase and Cancellation of Treasury Stock.")

The weighted average number of shares outstanding, which is used as the basis for the calculation of net income attributable to FUJIFILM Holdings per share in the consolidated earnings forecast for the fiscal year ending March 31, 2027, is calculated by deducting the number of treasury stock repurchased as described above from the number of issued shares outstanding (excluding treasury stock) as of March 31, 2026.

Notes**(1) Changes in status of material subsidiaries during the period**

(Company newly consolidated or removed from consolidation): None

(2) Changes in accounting principles

1. Changes in accounting policies accompanying amendment of accounting standards: None
2. Other changes in accounting policies: None

(3) Number of shares outstanding

1. Issued (including treasury stock):
2. Treasury stock:
3. Average number of shares:

As of March 31, 2026	1,243,877,184	As of March 31, 2025	1,243,877,184
As of March 31, 2026	38,547,368	As of March 31, 2025	39,043,399
Year ended March 31, 2026	1,203,646,419	Year ended March 31, 2025	1,203,306,280

This report is not reviewed.

Explanation of Appropriate Use of Forecast and Other Special Items

Statements regarding future events including forecasts of operating results are based on limited available information and reasonable assumptions as of today. The Company does not have the intention of guaranteeing the realization of future performance. Actual operating results are always subject to change significantly due to various matters. Assumptions for the forecast and warnings for users of the forecast are mentioned in the page 5, Outlook for the Fiscal Year ending March 31, 2027 of the section (1) Analysis of Results of Operations in 1. ANALYSIS OF OPERATING RESULTS AND CONSOLIDATED FINANCIAL POSITION.

[INDEX]

1.	ANALYSIS OF OPERATING RESULTS AND CONSOLIDATED FINANCIAL POSITION	
(1)	Analysis of Consolidated Operating Results.....	P.2
(2)	Analysis of Consolidated Financial Position	P.5
(3)	Basic Policy Regarding Distribution of Profits and Dividends Applicable to the Fiscal Year under Review and Subsequent Fiscal Year	P.6
2.	CORPORATE STRUCTURE OF THE FUJIFILM GROUP	P.6
3.	CORPORATE DIRECTION	P.7
4.	BASIC RATIONALE FOR SELECTION OF ACCOUNTING STANDARDS	P.10
5.	CONSOLIDATED FINANCIAL STATEMENTS	
(1)	Consolidated Balance Sheets	P.11
(2)	Consolidated Statements of Income and Consolidated Statements of Comprehensive Income ... (Consolidated Statements of Income)	P.14
	Year ended March 31	P.14
	Three months ended March 31	P.15
	(Consolidated Statements of Comprehensive Income)	P.16
	Year ended March 31	P.16
	Three months ended March 31	P.16
(3)	Consolidated Statements of Changes in Shareholders' Equity	P.17
(4)	Consolidated Statements of Cash Flows	P.18
(5)	Notes to Consolidated Financial Statements	P.19
	(Notes Relating to the Going Concern Assumption)	P.19
	(Summary of Significant Accounting Policies)	P.19
	(Segment Information)	P.20
	1) Year ended March 31	P.20
	2) Three months ended March 31	P.23
	(Amounts Per Share of Common Stock)	P.24
	(Significant Subsequent Events)	P.24

1. ANALYSIS OF OPERATING RESULTS AND CONSOLIDATED FINANCIAL POSITION

(1) Analysis of Consolidated Operating Results

Amount Unit: Billions of yen

	Year ended March 31, 2026 (From April 1, 2025 to March 31, 2026)		Year ended March 31, 2025 (From April 1, 2024 to March 31, 2025)		Change (Amount)	Change (%)
Domestic revenue	34.8%	1,168.7	34.4%	1,099.3	69.4	6.3%
Overseas revenue	65.2%	2,188.3	65.6%	2,096.5	91.8	4.4%
Revenue	100.0%	3,357.0	100.0%	3,195.8	161.1	5.0%
Operating income	10.4%	350.2	10.3%	330.2	20.1	6.1%
Income before income taxes	10.9%	366.6	10.7%	340.6	26.0	7.6%
Net income attributable to FUJIFILM Holdings	8.2%	276.7	8.2%	261.0	15.8	6.0%
Exchange rates (Yen / US\$)		¥151		¥152		(¥1)
Exchange rates (Yen / Euro)		¥175		¥164		¥11

In the fiscal year ended March 31, 2026, the Fujifilm Group recorded ¥3,357.0 billion in consolidated revenue (up 5.0% year-over-year), reflecting sales increases mainly in the bio CDMO, semiconductor materials and Imaging businesses. Operating income increased to ¥350.2 billion (up 6.1% year-over-year). Consolidated income before income taxes amounted to ¥366.6 billion (up 7.6% year-over-year) and consolidated net income attributable to FUJIFILM Holdings amounted to ¥276.7 billion (up 6.0% year-over-year). The effective currency exchange rates for the U.S. dollar and the euro against the yen were ¥151 and ¥175, respectively,

Revenue by Operating Segment

Amount Unit: Billions of yen

Segment	Year ended March 31, 2026 (From April 1, 2025 to March 31, 2026)	Year ended March 31, 2025 (From April 1, 2024 to March 31, 2025)	Change (Amount)	Change (%)
Healthcare	1,098.9	1,047.8	51.2	4.9%
Electronics	456.2	407.6	48.6	11.9%
Business Innovation	1,174.8	1,198.5	(23.7)	(2.0%)
Imaging	627.1	542.0	85.1	15.7%
Consolidated Total	3,357.0	3,195.8	161.1	5.0%

Operating Income by Operating Segment

Amount Unit: Billions of yen

Segment	Year ended March 31, 2026 (From April 1, 2025 to March 31, 2026)	Year ended March 31, 2025 (From April 1, 2024 to March 31, 2025)	Change (Amount)	Change (%)
Healthcare	63.6	79.9	(16.2)	(20.3%)
Electronics	100.9	75.1	25.8	34.4%
Business Innovation	63.7	74.6	(10.9)	(14.6%)
Imaging	160.0	139.2	20.8	14.9%
Corporate expenses etc.	(38.0)	(38.6)	0.6	-
Consolidated Total	350.2	330.2	20.1	6.1%

* From the consolidated first three months of the fiscal year, the chemical reagents business was reclassified from the Electronics segment, where it was included in the AF (Advanced Functional) materials business, to the Healthcare segment. Figures for the year ago quarter are also based on the segment classification after the above change.

Healthcare Segment

In the Healthcare segment, consolidated revenue amounted to ¥1,098.9 billion (up 4.9% year-over-year). Consolidated operating income amounted to ¥63.6 billion (down 20.3% year-over-year).

In the medical systems business, sales of endoscopes continued to increase in key markets, including Japan, the U.S. and Europe. Medical IT sales also grew as system services sales were solid in Japan, the U.S., Europe, the Middle East and other markets, mainly for the *SYNAPSE* Picture Archiving and Communication System (PACS). In addition, sales of in-vitro diagnostics (IVD) increased, including strong sales for *FUJI DRI-CHEM* blood biochemical testing equipment and materials. However, overall revenue for the medical systems business remained at the previous fiscal year's level due to factors such as lower demand for medical supplies in China. In March 2026, we launched *CALNEO Xair PLUS*, a lightweight and compact, mobile x-ray imaging device that helps streamline examination workflows, and added new products in the bronchoscope lineup, *EB-840S* and *EB-840T*, equipped with HD image CMOS sensors. We will continue to leverage our proprietary technologies to provide a wide range of products and services that meet the various demands of medical settings, to contribute to further streamlining diagnoses, advancing the quality of healthcare, and maintaining and promoting people's health.

In the bio CDMO business, revenue increased, driven mainly by contributions from the start of new large-scale manufacturing facilities in Denmark in the previous fiscal year, along with the resumption of operations of small- to medium-scale manufacturing facilities at the Texas site, which implemented operational adjustments during the previous fiscal year. In the fiscal year under review, we launched a new large-scale manufacturing plant in North Carolina, the United States, and commenced operations of eight 20,000-liter mammalian cell culture bioreactors, representing the first phase investment at the facility. Furthermore, in February 2026, we opened a drug substance manufacturing building for antibody drugs and a process development laboratory at our UK site. By responding to rapidly growing demand for antibody drugs contract manufacturing, we will further accelerate our business growth.

The LS (Life Sciences) solutions business*¹ posted higher revenue due to life sciences business delivering higher sales of culture media driven by increased usage by major pharmaceutical companies, as well as strong reagent sales amid a recovery in market demand, while the pharmaceutical business saw growth in revenue mainly with an expansion in contract manufacturing of investigational drugs for domestic COVID-19 vaccines.

*¹ The LS solutions business comprises life sciences business, pharmaceutical business, consumer healthcare business and CRO (Contract Research Organization) business.

Electronics Segment

In the Electronics segment, consolidated revenue amounted to ¥456.2 billion (up 11.9% year-over-year). Consolidated operating income amounted to ¥100.9 billion (up 34.4% year-over-year).

The semiconductor market, having experienced a period of stable growth due to the use of semiconductors in a wide range of products such as automobiles and home appliances, is now undergoing significant growth due to rising demand for AI semiconductors. Our semiconductor materials business has steadily captured this demand for AI semiconductors, resulting in a boost in revenue. Sales to major foundries continued to perform well, and sales to major semiconductor manufacturers in the U.S. and South Korea are also recovering. By product category, sales of NTI developers, copper interconnect CMP slurries—both of which we hold the top global market share—and advanced photoresists have grown in line with miniaturization and the increasing number of interconnect layers. With respect to back-end materials, sales of liquid polyimide for interlayer insulation films used in inter-chip connections have also grown, driven by expanding demand for advanced packaging for AI semiconductors. In February 2026, we completed a ¥5.0 billion investment in Rapidus Corporation, a company which aims to mass-produce leading-edge logic semiconductors. Through this investment, we are committed to realizing domestic mass production of leading-edge semiconductors and the development of Japan's semiconductor industry. Moreover, by providing Rapidus with a wide range of semiconductor materials and technologies, we will strongly support the company's development and manufacturing of leading-edge semiconductors. Additionally, by working closely with Rapidus on next-generation process development, we will enhance our technological capabilities and accelerate the development of materials for next-generation semiconductors.

In the AF (Advanced Functional) materials business, revenue increased due to the growing adoption of new display materials and strong sales of semiconductor resist materials.

Business Innovation Segment

In the Business Innovation segment, consolidated revenue amounted to ¥1,174.8 billion (down 2.0% year-over-year).

Consolidated operating income amounted to ¥63.7 billion (down 14.6% year-over-year).

In the business solutions business, revenue increased primarily due to growth in sales of digital transformation (DX)-related solutions driven by replacement demand in Japan with the end of Windows 10 support, as well as growth in services provided to local governments. In March 2026, we acquired ETG Global Information Technology Services Inc. in Turkey. By combining ETG Global's technical capabilities and IT talent base with the business foundation we have cultivated to date, we will globally expand our ERP system sales and implementation support business.

The office solutions business posted lower revenue, mainly due to the sluggish market conditions in China and Oceania, as well as a drop in sales in the Asia-Pacific region primarily caused by the discontinuation of low-profit products, as well as a decline in exports to Europe and the U.S.

The graphic communications business posted lower revenue due to lower sales of printing-plate materials in Europe and the U.S. and the discontinuation of unprofitable plate-making materials in the analog printing field. We launched *Revoria Press PC2120* in December 2025, a production printer that automates and streamlines printing operations using proprietary AI technology. Then in March 2026, we began offering *Revoria Cloud Production*, a cloud service that leverages AI for a more efficient print production management operations.

Imaging Segment

In the Imaging segment, consolidated revenue amounted to ¥627.1 billion (up 15.7% year-over-year).

Consolidated operating income amounted to ¥160.0 billion (up 14.9% year-over-year).

The consumer imaging business posted higher revenue, as sales of the *instax* instant photo systems continued to expand, surpassing cumulative sales of 100 million units. A wide variety of models popular among a broad range of users continue to have a solid growth in sales, including the mainstay models *instax mini I2* and *instax mini Evo*, along with models launched in the previous fiscal year, such as *instax WIDE 400*, *instax Link 3* and *instax WIDE Evo*. We also launched the entry-level *instax mini 41* with a classic design in April 2025, and *instax mini LiPlay+* in November 2025, which comes with an advanced version of a feature that combines sound and still images. Moreover, in January 2026, we launched *instax mini Evo Cinema*, an instant camera that can capture both videos (which users can “hand over” to others) and still images, and is equipped with the *Eras Dial* that recreates the appearance of footage from the 1930s to the current decade. We also launched *instax mini Link+*, a premium model in the *mini Link* smartphone printer series, offering novel ways to enjoy *instax* photos. Additionally, in December 2025, we announced our plan to expand the production facilities of *instax* films to meet growing global demand. We will continue to expand the world of *instax*, enabling people to enjoy instant photo printing and further enhancing the value and joy of photography.

In the professional imaging business, expanded sales of digital cameras contributed to higher revenue. In addition to solid sales of models launched in the previous fiscal year, the growth was driven by new products launched in the fiscal year under review, such as *FUJIFILM GFX100RF*, *FUJIFILM X-HF1* (“*X half*”), *FUJIFILM X-E5* and *FUJIFILM X-T30 III*. Further, we launched *FUJIFILM GFX ETERNA 55* in the fiscal year under review, our first dedicated filmmaking camera, and we will continue to provide new value to filmmaking sites through our color reproduction, large format rendering, and optical performance capabilities. We will continue to provide attractive products for digital camera users and the video industry by expanding our range of offerings, from the outstanding image quality with large format sensors in the *GFX* series and the best balance of image quality and size in the *X* series, to such new concept cameras as *FUJIFILM GFX100RF*, *X half* and *FUJIFILM GFX ETERNA 55*.

Outlook for the Fiscal Year ending March 31, 2027

Amount Unit: Billions of yen

	Outlook for the Fiscal Year ending March 31, 2027	Actual results for the Fiscal Year ended March 31, 2026	Change (% / Amount)
Revenue	3,470.0	3,357.0	3.4%
Operating income	365.0	350.2	4.2%
Income before income taxes	375.0	366.6	2.3%
Net income attributable to FUJIFILM Holdings	280.0	276.7	1.2%
ROE (%)	7.8	7.7	0.1pt
ROIC (%)	5.6	5.5	0.1pt
Exchange rates (Yen / US\$)	¥150	¥151	¥(1)
Exchange rates (Yen / Euro)	¥175	¥175	¥-

For the fiscal year ending March 31, 2027, the Company projects ¥3,470.0 billion in consolidated revenue (up 3.4% year-over-year), ¥365.0 billion in operating income (up 4.2% year-over-year), ¥375.0 billion in income before income taxes (up 2.3% year-over-year) and ¥280.0 billion in net income attributable to FUJIFILM Holdings (up 1.2% year-over-year).

The projected currency exchange rates for the U.S. dollar and the euro against the yen for the fiscal year ending March 31, 2027 are ¥150 and ¥175, respectively.

The impact of fluctuations in energy costs and raw material prices arising from heightened tensions in the Middle East has not been factored into the full-year outlook, as significant uncertainty remains regarding the situation going forward. In addition, sales in the Middle East have been only marginally affected, and the impact on revenue has likewise not been factored into the full-year outlook. However, as a risk scenario, if crude oil prices were to remain at USD 100 per barrel, we estimate a negative impact on operating profit of approximately ¥30.0 billion to ¥40.0 billion per quarter.

(2) Analysis of Consolidated Financial Position

(Assets, Liabilities, Shareholders' Equity and Cash Flows)

At the end of the fiscal year ended March 31, 2026, total assets increased by ¥803.9 billion to ¥6,053.8 billion compared with the end of the previous fiscal year (March 31, 2025) mainly due to an increase in property, plant and equipment. Total liabilities increased by ¥312.2 billion to ¥2,209.4 billion. Shareholders' equity increased by ¥491.1 billion to ¥3,839.6 billion. As a result, the current ratio decreased by 3.9 percentage points to 136.6%, the debt-equity ratio increased by 0.8 percentage points to 57.5%, and the equity ratio decreased by 0.4 percentage points to 63.4% compared with the end of the previous fiscal year. The Company maintains a stable level of asset liquidity and a sound capital structure.

In the fiscal year ended March 31, 2026, net cash provided by operating activities totaled ¥410.6 billion. Net cash used in investing activities amounted to ¥554.6 billion due to the acquisition of property, plants, equipment and other factors. As a result, free cash flow, or the sum of cash flow from operating and investing activities, was negative ¥144.0 billion. Net cash provided by financing activities amounted to ¥120.2 billion, mainly due to proceeds from long-term debts. As a result, cash and cash equivalents at the end of the fiscal year ended March 31, 2026 amounted to ¥170.6 billion, down ¥1.6 billion from the end of the previous fiscal year (March 31, 2025), as a result of the above cash flows and foreign exchange fluctuations.

(Reference) Cash Flow Related Indices (Consolidated)

	Year ended March 31, 2026 (From April 1, 2025 to March 31, 2026)	Year ended March 31, 2025 (From April 1, 2024 to March 31, 2025)
Ratio of shareholders' equity to total assets (%)	63.4	63.8
Ratio of market capitalization to total assets (%)	59.1	65.3
Ratio of interest-bearing debt to operating cash flow (years)	2.2	1.6
Interest coverage ratio (times)	82.2	48.9

Ratio of shareholders' equity to total assets : Shareholders' equity / Total assets

Ratio of market capitalization to total assets : Market capitalization (Year-end closing price x No. of shares outstanding at year-end*) / Total assets
*Excluding treasury shares

Ratio of interest-bearing debt to operating cash flow : Interest-bearing debts (corporate bond securities and short- and long-term debts) / Operating cash flow

Interest coverage ratio : Operating cash flow / interest paid

(3) Basic Policy Regarding Distribution of Profits and Dividends Applicable to the Fiscal Year under Review and Subsequent Fiscal Year

In addition to reflecting consolidated performance trends, dividends will be determined by taking into account such factors as the level of funds required to increase our corporate value in the future, including M&As, capital expenditures and R&D investments aimed at further expanding growth businesses. We have the policy on shareholder returns that puts emphasis on cash dividends, targeting the dividend payout ratio of 30%. Furthermore, we have flexibly conducted share repurchases in response to stock price trends while taking our cash flow at the time into account. As part of this policy, we have announced the execution of a share repurchase program with an upper limit of ¥30.0 billion in March 2026.

We are planning the year-end dividend to be ¥35.0 per share, and together with the interim dividend of ¥35.0 per share, the total cash dividend for the fiscal year under review is expected to amount to ¥70.0 per share.

In the fiscal year ending March 31, 2027, we plan to pay an interim dividend of ¥37.5 per share and a year-end dividend of ¥37.5 per share, for a total of ¥75.0 per share for the year.

2. CORPORATE STRUCTURE OF THE FUJIFILM GROUP

The disclosure is omitted since there are no significant changes in the business and group organizational structure from the latest Annual Securities Report filed on June 25, 2025.

3. CORPORATE DIRECTION

On the occasion of our 90th anniversary, we established the Fujifilm Group’s Purpose “Giving our world more smiles.” Since our foundation, we have brought smiles to people’s faces through our products and services based on our advanced and unique technologies. As we move towards our 100th anniversary and beyond, we remain committed to resolving social issues through all of our businesses, and each and every one of our employees will continue to challenge themselves with their aspirations to bring happy smiles to people around the world many times over. To achieve the Group Purpose, it is essential to: (1) develop new products and solutions, and invest in facilities to drive our sustainable business growth, (2) address Environmental, Social and Governance (ESG) issues to advance our efforts towards environmental sustainability, protection of human rights and ethical supply chain management, (3) invest in our people, implement innovations in developing our talent, enhance working conditions, and increase compensation standards as we focus on employee engagement and the full utilization of every employee’s unique skills and capabilities, and (4) ensure shareholder returns and deliver value to a broad range of stakeholders. To generate profits to fund these activities, the Group will increase its earning power by focusing on strong businesses that ensure long-term competitive advantage, and evolve into an even more profitable company by pursuing both economic and social value. Furthermore, by reinvesting the profits earned in (1), (2), (3) and (4) above, we will create a sustainable positive cycle.

In August 2017, we established our long-term CSR plan Sustainable Value Plan 2030 (hereinafter “SVP2030”). VISION2030, our medium-term management plan established in April 2024, is a concrete action plan to realize the goals of SVP2030. In VISION2030, we envision the ideal state of the Fujifilm Group in FY2030 as a collection of global top-tier businesses that further enhances the corporate value of the Group by promoting management that emphasizes profitability and capital efficiency, while changing the world one step at a time and creating value (more smiles) for various stakeholders. In FY2025, the second year of VISION2030, we achieved record highs for the fourth consecutive year in revenue, fifth consecutive year in operating income, and sixth consecutive year in net income attributable to FUJIFILM Holdings. We are making steady progress towards achieving VISION2030 by allocating funds secured through stronger portfolio management and cash flow management to capital expenditure in growth areas, primarily the bio CDMO and semiconductor materials businesses.

In FY2026, the global economy remained highly uncertain, reflecting various geopolitical factors, including the situations in Russia and Ukraine and Israel and Palestine, as well as growing concerns over a prolonged instability surrounding Iran. Other factors included volatility in energy markets, structural social shifts driven by the rapid advancement of artificial intelligence (AI), the rise of protectionist trade policies in various nations, and the tightening of resource security regarding rare earths and other critical resources. In Japan, while wage hikes and positive interest rates are gradually becoming the norm, the prolonged depreciation of the yen has led to surging raw material costs, forcing price revisions across numerous products. Under these circumstances, the Group will anticipate potential risks by maintaining a flexible and agile posture that quickly responds to various changes, as well as leverage our diverse business portfolio to improve the profitability of all businesses, promote stable cash generation, and evolve into a profitable company by accelerating business growth in the Healthcare and Electronics segments and intensifying our efforts to build a robust business platform that enables sustainable growth.

[Growth Strategy in the Healthcare Segment]

In the Healthcare segment, we will continue to provide products and services based on our proprietary AI technology, biotechnology and other cutting-edge technologies to resolve social issues in the medical field, such as enhancing QOL (quality of life) in an aging society and improving the medical environment in emerging countries. Through these efforts, we aim to increase revenue in the Healthcare segment in FY2026, exceeding ¥1 trillion in revenue for the third consecutive year following FY2024 and FY2025.

In the medical systems business, we will utilize AI and imaging technologies as the foundation for creating

value, introducing them in medical devices and IT services to offer new clinical value (including pre- and intraoperative support solutions) that only we can provide, while steadily expanding our recurring revenue businesses, such as services and consumables. Furthermore, our NURA health screening centers, which are geared towards emerging markets and have been released in five countries, have succeeded in providing consistent, high-quality checkups regardless of country or region, thanks to AI-powered diagnostic support as well as cutting-edge equipment such as CT scanners that feature our proprietary AI and deliver quality images by removing noise. We will continue to elevate the competitive advantage of the medical systems business through NURA, not only by providing value as a health screening business but also by incorporating the on-site challenges and latent needs identified through NURA's operations into the advancement of AI technology and new product development.

In the bio CDMO business, to meet the strong demand for antibody drugs, we launched a new large-scale manufacturing plant at our North Carolina site in the United States. In FY2025, following the capacity enhancement at our Denmark site in FY2024. The plant began operations of eight 20,000-liter mammalian cell culture bioreactors, representing the first phase investment. Contract manufacturing is steadily progressing in North Carolina, having concluded, among others, long-term manufacturing agreements with Janssen Supply Group, LLC, a Johnson & Johnson company, and Regeneron Pharmaceuticals, Inc. Against the backdrop of growing manufacturing demand in the U.S., we are working to bring forward the start of operations for facilities of the second phase of capital investments at this site. While FY2026 will be another year of upfront investments, we will expedite our business growth with large-scale manufacturing facilities as the main drivers.

In the LS solutions business, the life sciences business provides to major pharmaceutical companies and biotech firms culture media, reagents, cells and various other products and services that support different development stages, ranging from basic research and manufacturing to safety and quality testing, with the aim of meeting clients' needs in the field of drug discovery support. In the pharmaceutical business, we will continue to expand the manufacturing and sales of antibacterial agents such as penicillin. In addition, in 2025, we have completed the construction of one of the largest bio CDMO plants in Japan by adaptively reusing our existing Toyama site, with operations scheduled to begin from FY2027. At the new plant, we will establish a dual-use system capable of manufacturing biopharmaceuticals, such as antibody drugs and antibody-drug conjugates (ADCs), to meet customer needs during normal times, and mRNA vaccines and recombinant protein vaccines during pandemics. In the CRO business, we will expand our distinctive services, which make full use of, among others, evaluation technologies utilizing AI and iPS cells, both domestically and internationally by leveraging our proprietary peptide discovery technology as a core competency, primarily targeting customers engaged in the early stages of drug discovery, from basic research to non-clinical trials. In the consumer healthcare business, we will strengthen mail-order sales of our flagship brands, *ASTALIFT* (cosmetics) and *MetabARRIER* (supplements), and expand sales of *ASTALIFT MEN* (cosmetics for men) and *Hizatect* (foods with functional claims).

[Growth Strategy in the Electronics Segment]

In the Electronics segment, we will expand existing businesses and develop new businesses under the Electronics Strategy Headquarters through product portfolio establishment and strategy management on a customer application basis.

Demand has continued to grow in the semiconductor market, particularly for AI semiconductors. We expect that both miniaturization and higher integration in back-end processes will accelerate to improve semiconductor performance. To expedite the growth of our semiconductor materials business, we will leverage our strength in providing materials to nearly all stages in the semiconductor manufacturing process to offer one-stop solutions that help customers solve complex problems that cannot be addressed by a single material. Furthermore, by prioritizing local production, local consumption and "local support*2," our proactive investments in sites in Japan, the U.S., Europe and Asia not only support our customers' growth but also contribute to mitigating geopolitical risks, such as supply chain disruptions caused by conflicts. In addition, we are actively working to develop new markets, such as

steadily preparing for local expansion in India, including the acquisition of land for manufacturing sites, as the semiconductor market is expected to grow there. Regarding our core product, photoresists, we presented the latest technologies for advanced photoresists, with a focus on next-generation EUV technology, at SPIE Advanced Lithography + Patterning 2026, an international conference on semiconductor-related technologies held in February 2026. Moreover, in April 2026, we announced the development of the world's first PFAS-free negative-type ArF immersion resist. EUV, ArF and other new technologies have received high praise from customers, and the number of inquiries is steadily increasing. With respect to back-end materials, demand for polyimide films is anticipated to rise in response to the trend toward larger interposers and the growing need for the miniaturization of build-up substrates. Further, our CMP slurries that provide high-precision planarization during hybrid bonding, an advanced packaging process, are currently undergoing evaluation for their use. Multiple customers have voiced their high expectations regarding these materials. We have also begun full-scale sample assessments for advanced packaging, and efforts toward adoption are steadily growing.

In the AF materials business, we will maintain our strong market position of TAC products for displays and increase our share of materials for OLEDs. We will also leverage our technologies, such as data tape used in data centers—which are now being established worldwide due to increased demand for storage—the *Prescale* pressure measurement film used in the manufacturing process of semiconductors, displays, and other electronic devices, as well as polymers and photo acid generators for the growing semiconductor materials market, to expand the supply of differentiated products in the electronics sector.

*2 “Local support” refers to the support structure that enables customer issues to be addressed directly at local sites.

[Growth Strategy in the Business Innovation Segment]

In the Business Innovation segment, we began in FY2025 a full-scale adoption of AI for its application to devices and solutions, creating unique value as the industry's sole solutions partner that covers all areas of printing, from office and commercial printing (analog/digital) to industrial printing. In light of changes in the business environment, we will thoroughly advance structural reforms while shifting management resources more rapidly toward growth areas to establish a foundation for sustainable growth.

In the business solutions business, we will promote AI and security as the growth drivers across core systems, IT, and operational domains, while offering solutions tailored to each customer's business stage, thereby boosting value we provide and expanding our recurring business model. In the ERP solutions domain, we acquired ETG Global Information Technology Services Inc. in March 2026 (renamed to FUJIFILM ETG Global Inc. in the same month) to boost our delivery framework for ERP systems with Microsoft Dynamics 365 as its backbone. Going forward, we will expand our business into Europe and North America to accelerate our global presence. With respect to the IT solutions domain, we have launched *IT Expert Services* to support the operation and management of IT infrastructure environment for small and medium-sized companies that lack IT resources. In the business solutions domain, we are offering *FUJIFILM IWpro*, a cloud service that supports the cloud migration of our customers' infrastructure, as well as their business process transformation and DX. Since launching the *FUJIFILM IWpro Intelligent Assistant* option in January 2025, we have been continuously enhancing its AI capabilities. In March 2026, we added an AI chat feature, offering new value to our customers.

In the office solutions business, amid a gradual decline in print volumes, we will focus on the A3 color field, where we have a leading market share, and work to strengthen our environmental initiatives and production base. In sales, we will maintain and improve profitability by shifting to a more efficient sales structure and aim to expand sales of multifunctional devices in new markets by signing new agency contracts with major distributors in European countries and North America and by acquiring new OEM deals. In addition, as part of efforts to enhance services through the use of AI, we have started developing a new printing support feature that leverages Microsoft Copilot, Microsoft's generative AI assistant. This printing feature enhances the convenience of multifunction printers in Seven-Eleven convenience stores nationwide and we are aiming to launch it in FY2026. We will

continue promoting initiatives that expand the services we offer with our multifunction printers through the use of AI and other digital technologies.

In the graphic communications business, we are responding to changing trends in the commercial and packaging printing markets. Amid the decline in large-lot analog printing and monochrome printing and the increasing demand for high-mix, small-lot printing and color printing, we will expand sales by leveraging our strong customer base, where we hold leading market shares in printing plates, digital printers and industrial printheads, and further accelerating the shift to digital. In December 2025, we launched *Revoria Press PC2120* in Japan as a flagship model for the high-end professional printing market. Regarding inkjet inks and printheads, we will improve profitability by reorganizing the production structure. In parallel, we will leverage our unique products and technologies, such as high-productivity and high-quality printheads, as well as the highly stable aqueous pigment dispersion technology, to expand our business in the growing digital commercial and packaging printing markets, as well as in new areas where we expect market expansion through the advancement of inkjet technology.

[Growth Strategy in the Imaging Segment]

In the consumer imaging business, we will continue to expand our user base by constantly introducing captivating new products, including *instax mini LiPlay+* (launched in November 2025), a hybrid instant camera that comes with an advanced version of a feature that combines sound and still images, and *instax mini Evo Cinema* (launched in January 2026), an instant camera that can take both videos (which users can “hand over” to others) and still images, and is equipped with the *Eras Dial* that recreates the appearance of footage from the 1930s to the current decade. In addition, we will continue to tap into new printing demand by further expanding sales of commercial photo printers and creating new touchpoints with younger generations through alliances across various industries.

In the professional imaging business, we aim to grow our fan base by enhancing the multi-brand digital camera strategy, centered around the *X Series* and the *GFX Series* of digital cameras featuring color reproduction optimized for digital imaging, to meet emerging demand for more than just smartphone photography. Furthermore, with the launch of *FUJIFILM GFX ETERNA 55* in October 2025, our first dedicated filmmaking camera, we have made a full-scale entry into the video production market. The camera’s rich gradation and three-dimensional image expression have been well received both in Japan and internationally. In addition, we will promote new applications and expand sales areas for projectors and long-range surveillance cameras, while also proactively launching new solutions such as infrastructure inspection DX, utilizing the cutting-edge optical technology, image processing technology and AI.

4. BASIC RATIONALE FOR SELECTION OF ACCOUNTING STANDARDS

Due to the agreement related to the Eurodollar convertible bond issuance in 1970, the Group has prepared and disclosed its consolidated financial statements in accordance with accounting principles generally accepted in the U.S. The Company is considering the adoption of IFRS through addressing internal and external factors that affect both within and outside of Japan.

5. CONSOLIDATED FINANCIAL STATEMENTS

(1) Consolidated Balance Sheets

Amount Unit: Millions of yen

	As of March 31, 2026	As of March 31, 2025	Change
ASSETS			
Current assets:			
Cash and cash equivalents	170,553	172,111	(1,558)
Notes and accounts receivable:			
Trade	742,721	680,635	62,086
Lease receivable	31,750	32,821	(1,071)
Affiliated companies	2,737	2,371	366
Allowance for credit losses	(14,693)	(15,841)	1,148
	762,515	699,986	62,529
Inventories	600,796	543,976	56,820
Prepaid expenses and Other	185,169	165,608	19,561
Total current assets	1,719,033	1,581,681	137,352
Investments and long-term receivables:			
Investments in and advances to affiliated companies	37,617	37,785	(168)
Investment securities	43,672	72,298	(28,626)
Long-term lease receivables	49,181	47,431	1,750
Other long-term receivables	76,831	53,176	23,655
Allowance for credit losses	(1,511)	(1,396)	(115)
Total investments and long-term receivables	205,790	209,294	(3,504)
Property, plant and equipment:			
Land	121,419	110,067	11,352
Buildings and structures	1,173,654	934,470	239,184
Machinery, equipment and others	1,989,906	1,717,518	272,388
Construction in progress	979,735	888,245	91,490
	4,264,714	3,650,300	614,414
Less accumulated depreciation	(1,956,406)	(1,863,825)	(92,581)
Total property, plant and equipment	2,308,308	1,786,475	521,833
Other assets:			
Operating lease right-of-use assets	130,157	113,476	16,681
Goodwill, net	997,068	947,924	49,144
Other intangible assets, net	151,175	157,547	(6,372)
Deferred income taxes	41,210	42,895	(1,685)
Other	501,035	410,616	90,419
Total other assets	1,820,645	1,672,458	148,187
Total assets	6,053,776	5,249,908	803,868

Amount Unit: Millions of yen

	As of March 31, 2026	As of March 31, 2025	Change
LIABILITIES			
Current liabilities:			
Short-term debt	287,913	215,103	72,810
Notes and accounts payable:			
Trade	291,296	279,362	11,934
Construction	97,154	109,543	(12,389)
Affiliated companies	1,399	1,672	(273)
	389,849	390,577	(728)
Accrued income taxes	53,202	32,701	20,501
Accrued liabilities	280,017	252,788	27,229
Short-term operating lease liabilities	36,549	31,582	4,967
Other current liabilities	210,742	203,189	7,553
Total current liabilities	1,258,272	1,125,940	132,332
Non-current liabilities:			
Long-term debt	607,034	470,805	136,229
Accrued pension and severance costs	25,515	25,368	147
Long-term operating lease liabilities	95,517	84,795	10,722
Deferred income taxes	128,442	101,437	27,005
Other non-current liabilities	94,611	88,881	5,730
Total non-current liabilities	951,119	771,286	179,833
Total liabilities	2,209,391	1,897,226	312,165
EQUITY			
FUJIFILM Holdings shareholders' equity			
Capital	40,363	40,363	-
Common stock, without par value:			
Authorized: 2,400,000,000 shares			
Issued: 1,243,877,184 shares			
Retained earnings	3,117,407	2,930,151	187,256
Accumulated other comprehensive income	736,167	433,047	303,120
Treasury stock, at cost			
As of March 31, 2025:			
39,043,399 shares			
As of March 31, 2026:			
38,547,368 shares	(54,387)	(55,081)	694
Total FUJIFILM Holdings shareholders' equity	3,839,550	3,348,480	491,070
Noncontrolling interests	4,835	4,202	633
Total equity	3,844,385	3,352,682	491,703
Total liabilities and equity	6,053,776	5,249,908	803,868

Note: Details of accumulated other comprehensive income (loss)

	As of March 31, 2026	As of March 31, 2025	Change
Foreign currency translation adjustments	694,154	433,944	260,210
Pension liability adjustments	42,013	(862)	42,875
Unrealized gains (losses) on derivatives	-	(35)	35

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income
(Consolidated Statements of Income)

Year Ended March 31

Amount Unit: Millions of yen

	Year ended March 31, 2026 From April 1, 2025 to March 31, 2026		Year ended March 31, 2025 From April 1, 2024 to March 31, 2025		Change	
					Amount	%
Revenue:	%		%			
	100.0	3,356,969	100.0	3,195,828	161,141	5.0
Cost of sales:						
	59.2	1,987,457	59.3	1,895,749	91,708	4.8
Gross profit						
	40.8	1,369,512	40.7	1,300,079	69,433	5.3
Operating expenses:						
Selling, general and administrative	25.7	861,512	25.2	806,525	54,987	6.8
Research and development	4.7	157,790	5.1	163,399	(5,609)	(3.4)
	30.4	1,019,302	30.3	969,924	49,378	5.1
Operating income						
	10.4	350,210	10.3	330,155	20,055	6.1
Other income (expenses):						
Interest and dividend income		11,222		13,380	(2,158)	
Interest expense		(4,993)		(8,752)	3,759	
Foreign exchange gains (losses), net		(3,730)		(3,909)	179	
Gains (losses) on equity securities, net		(714)		(3,107)	2,393	
Other, net		14,634		12,827	1,807	
	0.5	16,419	0.3	10,439	5,980	57.3
Income before income taxes						
	10.9	366,629	10.7	340,594	26,035	7.6
Income taxes						
Current		80,713		81,809	(1,096)	
Deferred		10,548		(4,214)	14,762	
	2.7	91,261	2.4	77,595	13,666	17.6
Equity in net earnings (losses) of affiliated companies						
	0.1	1,929	0.0	(1,320)	3,249	-
Net income						
	8.3	277,297	8.2	261,679	15,618	6.0
Less: Net (income) loss attributable to the noncontrolling interests						
	0.0	(562)	0.0	(728)	166	-
Net income attributable to FUJIFILM Holdings						
	8.2	276,735	8.2	260,951	15,784	6.0

Three Months Ended March 31

Amount Unit: Millions of yen

	Three months ended March 31, 2026 From January 1, 2026 to March 31, 2026		Three months ended March 31, 2025 From January 1, 2025 to March 31, 2025		Change			
					Amount	%		
Revenue:	%	100.0	927,252	%	100.0	868,309	58,943	6.8
Cost of sales:		59.4	550,582		60.3	523,983	26,599	5.1
Gross profit		40.6	376,670		39.7	344,326	32,344	9.4
Operating expenses:								
Selling, general and administrative		25.5	236,136		22.5	195,513	40,623	20.8
Research and development		4.2	38,775		4.8	41,937	(3,162)	(7.5)
Operating income		29.6	274,911		27.3	237,450	37,461	15.8
Other income (expenses):								
Interest and dividend income			1,452			3,075	(1,623)	
Interest expense			(863)			(2,610)	1,747	
Foreign exchange gains (losses), net			645			(5,590)	6,235	
Gains (losses) on equity securities, net			(1,661)			(2,287)	626	
Other, net			3,107			3,983	(876)	
Income before income taxes		0.3	2,680		(0.4)	(3,429)	6,109	-
Income taxes		2.1	19,650		2.6	22,777	(3,127)	(13.7)
Equity in net earnings (losses) of affiliated companies		(0.1)	(1,284)		(0.1)	(1,172)	(112)	-
Net income		9.0	83,505		9.2	79,498	4,007	5.0
Less: Net (income) loss attributable to the noncontrolling interests		0.0	(145)		0.0	(86)	(59)	-
Net income attributable to FUJIFILM Holdings		9.0	83,360		9.1	79,412	3,948	5.0

(Consolidated Statements of Comprehensive Income)**Year Ended March 31**

Amount Unit: Millions of yen

	Year ended March 31, 2026 From April 1, 2025 to March 31, 2026	Year ended March 31, 2025 From April 1, 2024 to March 31, 2025	Change
Net income	277,297	261,679	15,618
Other comprehensive income (loss), net of tax:			
Foreign currency translation adjustments	260,471	(31,357)	291,828
Pension liability adjustments	42,875	20,635	22,240
Unrealized gains (losses) on derivatives	35	(33)	68
Total	303,381	(10,755)	314,136
Comprehensive income	580,678	250,924	329,754
Less: Comprehensive (income) loss attributable to noncontrolling interests	(823)	(545)	(278)
Comprehensive income attributable to FUJIFILM Holdings	579,855	250,379	329,476

Three Months Ended March 31

Amount Unit: Millions of yen

	Three months ended March 31, 2026 From January 1, 2026 to March 31, 2026	Three months ended March 31, 2025 From January 1, 2025 to March 31, 2025	Change
Net income	83,505	79,498	4,007
Other comprehensive income (loss), net of tax:			
Foreign currency translation adjustments	34,101	(109,185)	143,286
Pension liability adjustments	43,539	21,344	22,195
Unrealized gains (losses) on derivatives	-	(173)	173
Total	77,640	(88,014)	165,654
Comprehensive income (loss)	161,145	(8,516)	169,661
Less: Comprehensive (income) loss attributable to noncontrolling interests	(158)	117	(275)
Comprehensive income (loss) attributable to FUJIFILM Holdings	160,987	(8,399)	169,386

(3) Consolidated Statements of Changes in Shareholders' Equity

Amount Unit: Millions of yen

	Common stock	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss)	Treasury stock	FUJIFILM Holdings shareholders' equity	Noncontrolling interest	Total Equity
Balanced at April 1, 2024	40,363	-	2,741,416	443,619	(56,151)	3,169,247	4,068	3,173,315
Comprehensive income (loss):								
Net income			260,951			260,951	728	261,679
Foreign currency translation adjustments				(31,174)		(31,174)	(183)	(31,357)
Pension liability adjustments				20,635		20,635		20,635
Change in net unrealized losses on derivatives				(33)		(33)		(33)
Net comprehensive income						250,379	545	250,924
Purchases of treasury stock					(16)	(16)		(16)
Sales of treasury stock		1,151			1,086	2,237		2,237
Dividends paid to FUJIFILM Holdings shareholders			(72,289)			(72,289)		(72,289)
Dividends paid to noncontrolling interests							(291)	(291)
Stock acquisition rights		(697)				(697)		(697)
Transfer from additional paid-in capital to retained earnings		(73)	73			-		-
Equity transactions with non controlling interests and other		(381)				(381)	(120)	(501)
Balanced at March 31, 2025	40,363	-	2,930,151	433,047	(55,081)	3,348,480	4,202	3,352,682
Comprehensive income (loss):								
Net income			276,735			276,735	562	277,297
Foreign currency translation adjustments				260,210		260,210	261	260,471
Pension liability adjustments				42,875		42,875		42,875
Change in net unrealized losses on derivatives				35		35		35
Net comprehensive income						579,855	823	580,678
Purchases of treasury stock					(11)	(11)		(11)
Sales of treasury stock		694			705	1,399		1,399
Dividends paid to FUJIFILM Holdings shareholders			(90,396)			(90,396)		(90,396)
Dividends paid to noncontrolling interests							(332)	(332)
Stock acquisition rights		223				223		223
Transfer from additional paid-in capital to retained earnings		(917)	917			-		-
Equity transactions with non controlling interests and other							142	142
Balanced at March 31, 2026	40,363	-	3,117,407	736,167	(54,387)	3,839,550	4,835	3,844,385

(4) Consolidated Statements of Cash Flows

Amount Unit: Millions of yen

	Year ended March 31, 2026 From April 1, 2025 to March 31, 2026	Year ended March 31, 2025 From April 1, 2024 to March 31, 2025	Change
Operating activities			
Net income	277,297	261,679	15,618
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	172,371	163,567	8,804
(Gains) losses on equity securities, net	716	3,107	(2,391)
Deferred income taxes	10,548	(4,214)	14,762
Equity in net (gains) losses of affiliated companies, net of dividends received	(995)	1,856	(2,851)
Changes in operating assets and liabilities:			
Notes and accounts receivable	(23,942)	(5,348)	(18,594)
Inventories	(23,858)	(310)	(23,548)
Notes and accounts payable - trade	123	18,254	(18,131)
Changes in prepaid expenses and other current assets	(6,144)	(11,667)	5,523
Accrued income taxes and other liabilities	15,435	22,615	(7,180)
Others	(10,996)	(21,377)	10,381
Subtotal	133,258	166,483	(33,225)
Net cash provided by operating activities	410,555	428,162	(17,607)
Investing activities			
Purchases of property, plant and equipment	(521,583)	(502,794)	(18,789)
Purchases of software	(48,983)	(55,211)	6,228
Sales of property, plant and equipment	14,073	33,926	(19,853)
Proceeds from sales and maturities of marketable and investment securities	32,509	8,705	23,804
Purchases of marketable and investment securities	(5,650)	(462)	(5,188)
(Increase) decrease in time deposits, net	(2,781)	297	(3,078)
Increase in investments in and advances to affiliated companies	(181)	(42)	(139)
Acquisitions of businesses, net of cash acquired	(6,113)	(3,873)	(2,240)
Proceeds from sale of businesses, net of cash and cash equivalents disposed of	7,752	-	7,752
Others	(23,647)	(22,499)	(1,148)
Net cash used in investing activities	(554,604)	(541,953)	(12,651)
Financing activities			
Proceeds from long-term debt	170,000	350,000	(180,000)
Repayments of long-term debt	(67,602)	(82,320)	14,718
Increase (decrease) in short-term debt, net	102,324	(86,625)	188,949
Cash dividends paid to shareholders	(84,354)	(68,252)	(16,102)
Subsidiaries' cash dividends paid to noncontrolling interests	(332)	(292)	(40)
Purchases of stock for treasury	(12)	(16)	4
Capital transactions with noncontrolling interests	141	(671)	812
Others	84	(2,941)	3,025
Net cash provided by financing activities	120,249	108,883	11,366
Effect of exchange rate changes on cash and cash equivalents	22,242	(2,696)	24,938
Net decrease in cash and cash equivalents	(1,558)	(7,604)	6,046
Cash and cash equivalents at beginning of year	172,111	179,715	(7,604)
Cash and cash equivalents at end of year	170,553	172,111	(1,558)

(5) Notes to Consolidated Financial Statements
(Note Relating to the Going Concern Assumption)

None.

(Summary of Significant Accounting Policies)

(A) Scope of consolidated subsidiaries

Number of Subsidiaries : 258

Main companies : FUJIFILM Corporation, FUJIFILM Business Innovation Corp.
FUJIFILM Business Innovation Japan Corp. and others

(B) Scope of affiliated companies

Number of Affiliates : 27

Main companies : FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd. and others

(C) Significant Accounting Policies

The Company's consolidated financial statements are prepared in accordance with the U.S. generally accepted accounting principles (US GAAP). As there have been no material changes from the matters described in the most recent Annual Securities Report filed on June 25, 2025, disclosure thereof is omitted.

(Segment Information)**1. Year Ended March 31****(A) Operating Segment Information****a. Revenue**

Amount Unit: Millions of yen

	Year ended March 31, 2026 From April 1, 2025 to March 31, 2026		Year ended March 31, 2025 From April 1, 2024 to March 31, 2025		Change	
	Composition (%)		Composition (%)		Amount	%
Revenue:						
Healthcare	32.7	1,098,925	32.8	1,047,754	51,171	4.9
Electronics	13.6	456,157	12.8	407,607	48,550	11.9
Business Innovation	35.0	1,174,800	37.5	1,198,494	(23,694)	(2.0)
Imaging	18.7	627,087	17.0	541,973	85,114	15.7
Consolidated total	100.0	3,356,969	100.0	3,195,828	161,141	5.0

b. Expenses

Amount Unit: Millions of yen

	Year ended March 31, 2026 From April 1, 2025 to March 31, 2026		Year ended March 31, 2025 From April 1, 2024 to March 31, 2025		Change	
					Amount	%
R&D expenses						
Healthcare		53,346		61,279	(7,933)	(12.9)
Electronics		28,209		25,179	3,030	12.0
Business Innovation		55,406		54,507	899	1.6
Imaging		13,366		13,329	37	0.3
Subtotal		150,327		154,294	(3,967)	(2.6)
Corporate		7,463		9,105	(1,642)	(18.0)
Consolidated total		157,790		163,399	(5,609)	(3.4)
Other operating expenses						
Healthcare		981,942		906,593	75,349	8.3
Electronics		327,065		307,360	19,705	6.4
Business Innovation		1,055,682		1,069,373	(13,691)	(1.3)
Imaging		453,718		389,430	64,288	16.5
Subtotal		2,818,407		2,672,756	145,651	5.4
Corporate		30,562		29,518	1,044	3.5
Consolidated total		2,848,969		2,702,274	146,695	5.4

c. Operating income

Amount Unit: Millions of yen

	Year ended March 31, 2026 From April 1, 2025 to March 31, 2026		Year ended March 31, 2025 From April 1, 2024 to March 31, 2025		Change	
	Margin (%)		Margin (%)		Amount	%
Operating Income (Loss):						
Healthcare	5.8	63,637	7.6	79,882	(16,245)	(20.3)
Electronics	22.1	100,883	18.4	75,068	25,815	34.4
Business Innovation	5.4	63,712	6.2	74,614	(10,902)	(14.6)
Imaging	25.5	160,003	25.7	139,214	20,789	14.9
Total		388,235		368,778	19,457	5.3
Corporate expenses etc.		(38,025)		(38,623)	598	-
Consolidated total	10.4	350,210	10.3	330,155	20,055	6.1

Note: The major products and services of each operating segment are as follows:

Healthcare:	Equipment and materials for medical systems, contract development and manufacturing organization of biopharmaceuticals, drug discovery support such as iPS cells, cell culture media and reagents, pharmaceuticals, cosmetics and supplements, etc.
Electronics:	Semiconductor materials, display materials, industrial equipment, fine chemicals, etc.
Business Innovation:	Solutions and services, digital MFPs, equipment and materials for graphic communications, inks and industrial inkjet printheads, etc
Imaging:	Instant photo systems, color films, services and equipment for photofinishing, digital cameras and optical devices, etc.

d. Total Assets

Amount Unit: Millions of yen

	As of March 31, 2026	As of March 31, 2025	Change	
			Amount	%
Total assets:				
Healthcare	3,227,034	2,607,431	619,603	23.8
Electronics	821,265	761,391	59,874	7.9
Business Innovation	1,469,229	1,373,286	95,943	7.0
Imaging	423,126	364,437	58,689	16.1
Subtotal	5,940,654	5,106,545	834,109	16.3
Corporate	113,122	143,363	(30,241)	(21.1)
Consolidated total	6,053,776	5,249,908	803,868	15.3

e. Depreciation and amortization, and Capital expenditures

Amount Unit: Millions of yen

	Year ended March 31, 2026 From April 1, 2025 to March 31, 2026	Year ended March 31, 2025 From April 1, 2024 to March 31, 2025	Change	
			Amount	%
Depreciation and amortization:				
Healthcare	74,461	62,739	11,722	18.7
Electronics	30,677	28,704	1,973	6.9
Business Innovation	45,754	51,776	(6,022)	(11.6)
Imaging	17,181	17,382	(201)	(1.2)
Corporate	4,298	2,966	1,332	44.9
Consolidated total	172,371	163,567	8,804	5.4
Capital expenditures:				
Healthcare	444,685	465,883	(21,198)	(4.6)
Electronics	38,533	40,284	(1,751)	(4.3)
Business Innovation	63,821	73,035	(9,214)	(12.6)
Imaging	29,031	21,602	7,429	34.4
Corporate	5,906	6,377	(471)	(7.4)
Consolidated total	581,976	607,181	(25,205)	(4.2)

*From the consolidated first three months of the fiscal year, the chemical reagents business was reclassified from the Electronics segment, where it was included in the AF materials business, to the Healthcare segment. Figures for the year-ago quarter are also based on the segment classification after the above change.

(B) Geographic Information**a. Long - lived assets**

Amount Unit: Millions of yen

	As of March 31, 2026	As of March 31, 2025	Change	
			Amount	%
Long - lived assets				
Japan	432,956	408,084	24,872	6.1
The Americas	882,660	643,690	238,970	37.1
Europe	911,253	664,752	246,501	37.1
Asia and others	81,439	69,949	11,490	16.4
Consolidated total	2,308,308	1,786,475	521,833	29.2

b. Overseas revenue (Destination Base)

Amount Unit: Millions of yen

	Year ended March 31, 2026 From April 1, 2025 to March 31, 2026		Year ended March 31, 2025 From April 1, 2024 to March 31, 2025		Change	
	Composition (%)		Composition (%)		Amount	%
Revenue:						
Domestic	34.8	1,168,682	34.4	1,099,302	69,380	6.3
Overseas:						
The Americas	19.6	657,898	20.2	646,904	10,994	1.7
Europe	17.3	581,133	17.0	544,628	36,505	6.7
Asia and others	28.3	949,256	28.3	904,994	44,262	4.9
Subtotal	65.2	2,188,287	65.6	2,096,526	91,761	4.4
Consolidated total	100.0	3,356,969	100.0	3,195,828	161,141	5.0

Note: The presentation of the Overseas Revenue (Destination Base) has been classified and disclosed based on the customer's location.

2. Three months ended March 31

(A) Operating Segment Information

Revenue

Amount Unit: Millions of yen

	Three months ended March 31, 2026 From January 1, 2026 to March 31, 2026		Three months ended March 31, 2025 From January 1, 2025 to March 31, 2025		Change	
	Composition (%)		Composition (%)		Amount	%
Revenue:						
Healthcare	36.0	333,606	36.4	316,454	17,152	5.4
Electronics	13.7	127,482	11.5	100,099	27,383	27.4
Business Innovation	35.0	324,783	38.7	336,446	(11,663)	(3.5)
Imaging	15.2	141,381	13.3	115,310	26,071	22.6
Consolidated total	100.0	927,252	100.0	868,309	58,943	6.8

* From the consolidated first three months of the fiscal year, the chemical reagents business was reclassified from the Electronics segment, where it was included in the AF Materials business, to the Healthcare segment. Figures for the year-ago quarter are also based on the segment classification after the above change.

Note: The major products and services of each operating segment are as follows:

Healthcare:	Equipment and materials for medical systems, contract development and manufacturing organization of biopharmaceuticals, drug discovery support such as iPS cells, cell culture media and reagents, pharmaceuticals, cosmetics and supplements, etc.
Electronics:	Semiconductor materials, display materials, industrial equipment, fine chemicals, etc
Business Innovation:	Solutions and services, digital MFPs, equipment and materials for graphic communications, inks and industrial inkjet printheads, etc.
Imaging:	Instant photo systems, color films, services and equipment for photofinishing, digital cameras and optical devices, etc.

(B) Geographic Information

Overseas Revenue (Destination Base)

Amount Unit: Millions of yen

	Three months ended March 31, 2026 From January 1, 2026 to March 31, 2026		Three months ended March 31, 2025 From January 1, 2025 to March 31, 2025		Change	
	Composition (%)		Composition (%)		Amount	%
Revenue:						
Domestic	37.0	342,771	38.4	333,655	9,116	2.7
Overseas:						
The Americas	18.5	171,881	18.4	159,692	12,189	7.6
Europe	16.6	154,017	17.5	152,381	1,636	1.1
Asia and others	27.9	258,583	25.6	222,581	36,002	16.2
Subtotal	63.0	584,481	61.6	534,654	49,827	9.3
Consolidated total	100.0	927,252	100.0	868,309	58,943	6.8

(Amounts Per Share of Common Stock)

	Year ended March 31, 2026 From April 1, 2025 to March 31, 2026	Year ended March 31, 2025 From April 1, 2024 to March 31, 2025
FUJIFILM Holdings shareholders' equity per share	3,185.79	2,779.50
Basic net income attributable to FUJIFILM Holdings per share	229.65	216.67
Diluted net income attributable to FUJIFILM Holdings per share	229.45	216.46

(Significant Subsequent Events)

None.